Though it bills itself as an ophthalmic drug company, Acuity Pharmaceuticals continues to make a name for itself in the RNAi field.
Last week, the company announced that it had in-licensed from ZaBeCor an siRNA targeting Syk kinase and related intellectual property for ophthalmic indications. Specific terms of the deal, which gives Acuity its second RNAi-based drug candidate, were not disclosed.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
